<DOC>
	<DOCNO>NCT02750514</DOCNO>
	<brief_summary>The purpose study determine whether nivolumab combination therapy effective nivolumab alone people advance lung cancer .</brief_summary>
	<brief_title>A Study Test Combination Treatments People With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Advanced Non Small Cell Lung Cancer ( NSCLC ) Eastern Cooperative Oncology Group ( ECOG ) Performance status â‰¤ 1 Life expectancy least 3 month recent chemotherapy immunotherapy treatment Must least 1 lesion measurable disease Subjects certain mutation treat targeted therapy prior enrollment Subjects need daily oxygen therapy People autoimmune disease Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>